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Almost 50 years after the first description of a patient with
a mitochondrial disease (Luft et al. 1962), there now is an
extraordinarily rapid development in mitochondrial medi-
cine. In the first 30 years of mitochondrial disease research,
the focus was centered on unravelling the aetiology of the
high variety of manifestations of mitochondrial dysfunc-
tion. Currently, one of the most important focuses is on
providing a cure for these devastating diseases. In the first
chapter of this issue, Salvatore DiMauro will guide you
through the history of mitochondrial medicine, chronologi-
cally discussing important discoveries and dedicated mito-
chondriacs diseases (DOI: 10.1007/s10545-010-9082-x).
Besides the ongoing development of new techniques to
study mitochondrial (patho)physiology, genetics and organ-
elle dynamics, it is the individual patients that taught us most
about the physiology of the mitochondria.
Identifying mitochondrial disease patients and subse-
quently establishing the diagnosis is one of the clinical
challenges in mitochondrial medicine, because of the
clinical heterogeneity and the ever-expanding phenotype.
Before the diagnosis can be confirmed by biochemical
analysis of fresh tissue acquired by a muscle biopsy, the
indication of the muscle biopsy must be set on clinical and
biochemical grounds, supported by the use of biomarkers.
Anu Suomalainen describes the various parameters which
can be used to support the clinical diagnosis of mitochondrial
disease (DOI: 10.1007/s10545-010-9222-3). Unfortunately,
most biomarkers used in every day practice, such as lactate
and alanine, are not 100% sensitive and specific. Various
new approaches are described, such as the measurement of
intracellular glutathione levels, proteomics and lipidomics.
After the clinical suspicion of mitochondrial disease, it
is important to confirm the diagnosis by biochemical
examination of fresh muscle tissue. The techniques used
to analyze mitochondrial function are more and more
automated and therefore become quicker. To confirm a
primary mitochondrial dysfunction, a mutation in one of
the structural or facilitating proteins should be confirmed.
Previously, detecting and proving the pathogenicity of a
DNA mutation, either in nuclear or in mitochondrial
DNA, required a huge amount of labor. Thanks to many
enduring researchers, numerous mutations in mitochondrial
DNA (mtDNA) and nuclear DNA have been found. Since the
commercial availability of the MitoChip, the sequencing
velocity of mtDNA has increased immensely and many new
mutations and polymorphisms are found constantly. In
nuclear DNA, the new high-throughput DNA sequencing
methods along with bioinformatical analysis will certainly
speed up the identification of new genes and mutations
(DOI: 10.1007/s10545-010-9081-y).
With the identification of mutations in nuclear genes, it
has become possible to create an animal model with a
mutation similar to the gene defect seen in patients. Two
mouse models have been created with an isolated complex I
deficiency, which is the most common biochemical defect
in mitochondrial disease (DOI: 10.1007/s10545-009-9005-x).
Both models show a striking similarity with the clinical and
biochemical phenotype seen in human complex I patients.
Many advanced technologies have been used to design
the perfect drug to combat mitochondrial disease. Most of
the experiments are still at the cellular level. Several
strategies have been practiced/practised to develop mito-
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chondrial treatment options (Koene & Smeitink 2009),
namely altering the balance between mutated and healthy
DNA, metabolic manipulation and transcription regulation,
gene therapy and the prevention of transmission of mtDNA
mutations.
Most of the above mentioned approaches are only
applicable in mtDNA mutations, as is the case for the
attempts to alter the balance between mutated and healthy
mtDNA (heteroplasmy) (DOI: 10.1007/s10545-010-9122-6).
Since cellular dysfunction occurs only when the threshold
for heteroplasmy is exceeded, stimulating replication of the
healthy mtDNA or reducing the mutated mtDNA will
potentially increase cellular function. Smith and Lightowlers
describe several ways to manipulate heteroplasmy by, for
instance, exercise training or genetic manipulation.
Another rational way to combat mitochondrial dysfunc-
tion is to correct the metabolic alterations seen at the
cellular level (DOI: 10.1007/s10545-010-9162-y). Since
these alterations are seen in both mitochondrial and nuclear
mutations as well as secondary mitochondrial dysfunction,
this approach is theoretically applicable in all mitochondrial
diseases. In the past decade, the consequences of oxidative
phosphorylation dysfunction, such as a increased production
of reactive oxygen species, have been mapped in detail and
automated quantitative live-assays have been developed to
visualize these parameters (Koopman et al. 2009). Many
research groups around the world have established ways to
manipulate mitochondrial pathology in cellular models. Now
is the time to test these compounds in vivo.
Gene therapy to minimize the negative impact of
mtDNA mutations on cell viability has also shown
promising results at the cellular level (DOI: 10.1007/s10545-
010-9131-5). The most promising ways to manipulate the
genetic environment of the mitochondria are afforded by
using import of wild-type copies of DNA or RNA into
mitochondria, manipulating the mitochondrial genetic con-
tent or rescuing a defect by expressing an engineered gene
product from the nucleus (allotopic or xenotopic expression).
However, utilization of these techniques in in vivo studies is
frustrated by a lack of reliable animal models and difficulties
in the delivery and expression of the therapeutic gene.
Despite the lack of a cure, it is important to recognize
mitochondrial disorders as they are a frequent cause of inborn
errors of metabolism. Therefore, it is important to create
mitochondrial-awareness among doctors, to detect and diag-
nose the mitochondriopathy. Despite the apparent lack of
therapy, the confirmation of a mitochondrial disease is
important to prevent secondary mitochondrial dysfunction as
seen in malnutrition or deconditioning (Morava et al. 2006).
The confirmation of a diagnosis can also be of great
importance in family planning, since there are experimental
ways to prevent transmission of mtDNA mutations and to
perform prenatal diagnostics in patients with nuclear
mutations. As long as we cannot cure mitochondrial
diseases, this approach is of great value for parents having
a child with mitochondrial disease.
This issue will give an overview of some hopeful
breakthroughs and the many challenges remaining in
pursuit of the first effective treatment for mitochondrial
disease. There seems to be light at the end of the tunnel,
although currently it is difficult to predict when such
treatment will become available.
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